Skip to content

RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage

RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01070641
Enrollment
148
Registered
2010-02-18
Start date
2002-06-30
Completion date
2011-07-31
Last updated
2010-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Hypertension

Keywords

CARVEDILOL, VARICEAL BAND LIGATION, PRIMARY PROPHYLAXIS

Brief summary

Aim To compare Carvedilol with variceal band ligation in the prevention of first variceal bleed. End points of trial Primary: Variceal hemorrhage Secondary: Death Study design Randomised controlled clinical trial. Results analysed for the above end points on an intention-to-treat basis.

Detailed description

Patients from the Gastroenterology section of the Aga Khan University, Karachi, with liver cirrhosis and on endoscopy having grade II, or larger oesophageal varices and who have not bled previously from varices. Method All suitable patients will be recruited after informed consent is given. Randomisation of treatment is by sealed envelopes prepared in batches of 20. Carvedilol This will be administered as a once daily dose of 12.5mg. Variceal band ligation Endoscopy will be performed ever two weeks until eradication of oesophageal varices. Eradication is achieved when no varices or only grade I varices (varices which are small and flatten on air insufflations in the oesophagus) are present. Subsequent endoscopy sessions will be progressively less frequent, at intervals of 3 months, 6 months and 12 months thereafter. Should varices recur, the protocol for eradication as described above will be re-instituted. Follow-up This will take place in a dedicated clinic. First visit is six weeks after initiation of treatment and three monthly thereafter. Clinical and laboratory parameters will be obtained at each visit. All patients with alcoholic liver disease will be asked to provide an up-to-date status on drinking. Treatment will cease upon reaching any of these end-points: variceal haemorrhage, death or liver transplantation. Duration of follow-up is defined as time from randomisation to the above end points or to the last follow-up date available.

Interventions

DRUGCarvedilol

Carvedilol 12.5mg QD

Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices

Sponsors

Aga Khan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with liver cirrhosis and on endoscopy having grade II, or larger oesophageal varices and who have not bled previously from varices.

Exclusion criteria

* Age \<18 or \> 75 years. * Pregnant or lactating patients: patients of childbearing age who are not on contraception. * Allergy to Carvedilol. * Already on beta blockers or nitrates. * Presence of malignancy that will significantly affect survival. * Presence of severe systemic illness e.g. cardiorespiratory, active sepsis. * Psychiatric disease or learning difficulty that will prevent the granting of informed consent. * Presence of obstructive airways disease.

Design outcomes

Primary

MeasureTime frame
Variceal hemorrhageone year

Secondary

MeasureTime frame
deathone year

Countries

Pakistan

Contacts

Primary ContactSyed Hasnain A Shah, MBBS, FRCP
hasnain.alishah@aku.edu00922134930051

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026